Summary
Health Catalyst reported second quarter 2020 total revenue of $43.3 million, up 18% from the prior-year quarter. For the six months ended June 30, 2020, total revenue was $88.4 million, up 23%. The company said growth came from new DOS Subscription Customers and higher technology access fees from contractual escalators. Professional services revenue growth was limited by temporary discounts given to health system customers facing COVID-19 financial strain. Those discounts pushed Adjusted Professional Services Gross Margin down to 21% from 37% a year earlier. Total Adjusted Gross Margin was 49%, down from 52%. Adjusted Technology Gross Margin increased to 69% from 65%. The company signed multiple new DOS subscription customers in the first half, but net new additions were lower than originally planned because of pandemic-related procurement distractions. Health Catalyst employed more than 900 team members as of the quarter.
Profitability weakened. Loss from operations was $15.6 million for the quarter, and the operating loss widened 67% from the prior-year quarter. Operating margin was negative 36.2%, down 10.7 percentage points from the prior-year quarter. Net loss was $27.2 million, or negative $0.71 per diluted share. The net loss widened 154% year over year. The company recorded a loss on extinguishment of debt after prepaying its OrbiMed credit facility, which contributed to the wider loss. Stock-based compensation also rose. Adjusted EBITDA, a non-GAAP measure, was negative $4.2 million, an improvement from negative $5.7 million in the prior-year quarter. For the six months, net loss was $44.7 million, or negative $1.19 per diluted share. Adjusted EBITDA for the six months was negative $10.2 million, compared with negative $12.4 million a year earlier.
Cash flow improved in the quarter but remained negative. Operating cash flow was negative $0.75 million for the quarter, an improvement of 91.1% from the prior-year quarter. For the six months ended June 30, 2020, operating cash flow was negative $17.5 million, a decline of 28.4% from the prior-year period. Capital expenditures were $0.56 million for the quarter, up 50% year over year, and $1.07 million for the six months, essentially flat. Deferred revenue stood at $37.3 million at June 30, 2020, down 10.6% from a year earlier. Remaining performance obligations were $44.2 million, down 30.8%. The company issued $230.0 million of 2.50% convertible senior notes due 2025 and used $57.0 million to repay its OrbiMed credit facility.
For the third quarter of 2020, Health Catalyst guided Adjusted EBITDA between negative $8.9 million and negative $6.9 million. For the full year 2020, it guided Adjusted EBITDA between negative $25.5 million and negative $22.5 million. The company also provided total revenue guidance for the third quarter and full year but did not reconcile Adjusted EBITDA guidance to net loss. Management noted that more than 90% of revenue is recurring, that there was no DOS Subscription Customer churn from COVID-19, and that customer platform usage reached new highs. Operational highlights included a Gallup team member satisfaction score in the 99th percentile and the seventh annual Healthcare Analytics Summit, which will be virtual in September with the theme "healthcare analytics in the new normal."
Key risks include the uncertain duration of COVID-19, potential customer financial strain, delayed new customer additions, the transition to Microsoft Azure increasing technology costs, lower retention from Medicity customers, and the company's upcoming loss of emerging growth company status, which will require auditor attestation of internal controls. The company's professional services discounts are expected to negatively impact Adjusted Professional Services Gross Margin for the third quarter of 2020, though the impact should be limited compared to the second quarter. The company also faces the need to recruit and retain qualified team members, the possibility of litigation or a security incident, and the loss of one or more key customers or partners. Changes in laws and regulations applicable to its business model could also affect results. The new headquarters lease requires future lease payments of approximately $31.7 million over an 11-year term.
Forecast
Reported figures
GAAP, from SEC filings| Metric | Q2 FY2020 | Q1 FY2020 | QoQ | Q2 FY2019 | YoY |
|---|---|---|---|---|---|
| Revenue | $43.3M | $45.1M | -4.1% | $36.8M | +17.5% |
| Research & development | $12.1M | $13.1M | -7.8% | $9.7M | +24.2% |
| Sales & marketing | $12.5M | $13.5M | -7.3% | $10.4M | +20.4% |
| General & administrative | $8.1M | $9.7M | -16.4% | $6.1M | +32.0% |
| Total operating expenses | $35.8M | $39.2M | -8.6% | $28.5M | +25.7% |
| Operating income (loss) | -$15.6M | -$18.1M | +13.6% | -$9.4M | -67.0% |
| Operating margin | -36.1% | -40.1% | +4.0 pp | -25.4% | -10.7 pp |
| Net income (loss) | -$27.2M | -$17.5M | -55.4% | -$10.7M | -154.2% |
| Net margin | -62.8% | -38.8% | -24.1 pp | -29.1% | -33.8 pp |
Risks
The COVID-19 pandemic has disrupted healthcare provider customers, delayed higher-margin elective procedures, and increased customer financial strain. MD&A states first-half 2020 net new DOS subscription customer additions were lower than originally anticipated and that temporary professional services discounts contributed to Adjusted Professional Services Gross Margin decreasing from 37% for the three months ended June 30, 2019 to 21% for the three months ended June 30, 2020.
The sales cycle for a new customer has averaged 11 months and in some cases exceeded 24 months, and the company says COVID-19 could lengthen it, delaying revenue relative to operating expenses. MD&A reports first-half 2020 net new DOS subscription customer additions were lower than originally anticipated due to health system procurement distraction from the pandemic.
The three largest customers during 2019 comprised 4.6%, 3.6%, and 3.6% of revenue, or 11.8% in the aggregate, and the loss or renegotiation of any largest customer contract could adversely affect results. Deferred revenue was $37.30 million in FY2020 Q2, down 10.6% from FY2019 Q2, and remaining performance obligations were $44.20 million in FY2020 Q2, down 30.8% from FY2019 Q2.
The company reported net loss of $27.18 million in FY2020 Q2 compared with net loss of $10.69 million in FY2019 Q2, with the loss widening, and operating loss of $15.64 million compared with $9.36 million, also widening. Operating margin was -36.2% in FY2020 Q2 compared with -25.4% in FY2019 Q2, so profitability remains a significant challenge.
The data platform depends on sourcing clinical, financial, and operational data from third-party vendors, and information blocking practices could inhibit access. The 21st Century Cures Act Final Rule anti-information blocking provisions do not go into effect until November 2, 2020, with additional enforcement discretion, and it is unclear whether exceptions will be interpreted broadly, so data access or Solution effectiveness may be limited.
Professional services have lower gross margins than technology revenue, and temporary COVID-19 related discounts reduced Adjusted Professional Services Gross Margin from 37% for the three months ended June 30, 2019 to 21% for the three months ended June 30, 2020. The company anticipates these discounts will also negatively impact Adjusted Professional Services Gross Margin for the three months ended September 30, 2020, though the impact should be limited compared to the three months ended June 30, 2020.
The company is transitioning customers from its private data center and on-premise deployments to Microsoft Azure, and hosting customers in Azure is more costly on a per-customer basis. This transition is expected to increase cost of technology revenue and create a headwind against increases in Adjusted Technology Gross Margin; unsuccessful migration could cause service outages, downtime, customer dissatisfaction, and non-renewals.
Medicity customers have historically generated a lower Dollar-based Retention Rate than DOS Subscription Customers, and the company expects flat to declining revenue from Medicity customers in the foreseeable future. If cross-sell efforts and technology integration strategies are unsuccessful, this could negatively impact revenue growth rates over time.
In April 2020 the company issued $230.0 million in aggregate principal amount of 2.50% Convertible Senior Notes due 2025 and used $57.0 million of proceeds to prepay in full the OrbiMed credit facility. This increases fixed obligations and potential dilution risk from the Notes and related capped call transactions.
The market for healthcare solutions is intensely competitive, and the company faces competition from EHR companies such as Epic Systems and Cerner and larger analytics vendors such as Optum Analytics and IBM. Increased competition is likely to result in pricing pressures, which could negatively impact sales, profitability, or market share.
The company states that on the last business day of FY2020 Q2 the aggregate worldwide market value of common stock held by non-affiliates exceeded $700 million, so as of December 31, 2020 it will be a large accelerated filer and will cease to be an emerging growth company. It will lose the Section 404(b) auditor attestation exemption, increasing compliance costs and management attention.
Healthcare laws and regulations are rapidly evolving and may change significantly; the ACA remains in effect but it is unclear what effect the Fifth Circuit ruling that the individual mandate is unconstitutional and remand to the lower court will have on its status. Changes in healthcare laws or trends could affect demand for the Solution, cause existing contracts to be terminated, and make negotiating future contracts more difficult.
SaaS KPIs
All quarters →Adjusted EBITDA
Adjusted Professional Services Gross Margin
Adjusted Technology Gross Margin
Total Adjusted Gross Margin
Recurring revenue
Summary, forecast, risks and KPIs are extracted from Health Catalyst, Inc.'s SEC filings for Q2 FY2020 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Oct 21, 2026.